Google, IBM, Intel, Coke and Johnson & Johnson are part of Zacks Earnings Preview:
CHICAGO, July 15, 2013 /PRNewswire/ -- Zacks.com releases the list of companies likely to issue earnings surprises. This week's list includes Google (Nasdaq: GOOG-Free Report), IBM (NYSE: IBM-Free Report), Intel (Nasdaq: INTC-Free Report), Coke (NYSE: KO-Free Report) and Johnson & Johnson (NYSE: JNJ-Free Report).
To see more earnings analysis, visit http://at.zacks.com/?id=3207.
Every day, Zacks.com makes their Bull Stock of the Day available, free of charge. To see it, click here.
Q2 Earnings Season Into High Gear
The 2013 Q2 earnings season gets into high gear this week as earnings reports from 178 companies come out, including 76 from the S&P 500. By the end of this week, we have earnings reports from more than a fifth of the index's total membership; giving us a good enough sample size to judge the Q2 earnings season.
This week's reporting docket is heavy with Finance sector results, but we have plenty of bellwethers from other key sectors on deck as well, which makes this week's reports a fairly representative sample. From Google (Nasdaq: GOOG-Free Report), IBM (NYSE: IBM-Free Report), and Intel (Nasdaq: INTC-Free Report) to Coke (NYSE: KO-Free Report) and Johnson & Johnson (NYSE: JNJ-Free Report) and much more in between, this week's reports span the full spectrum of the economy. While earnings reports from almost 80% of the S&P 500 companies will still be awaited by the end of the week, the trends established this week will likely carry through the rest of this reporting cycle with only minor changes.
With respect to the results thus far, we have seen Q2 results from 29 S&P 500 members (as of Friday, July 12th). These results provide a bit of a mixed picture, though not materially different from what we saw in Q1. Earnings and revenue growth for these 29 companies are comparable to what these same companies achieved in 2013 Q1. But the beat ratios (% of companies coming out with positive surprises) are modestly weaker on the earnings side and about the same on the revenue side. Given the very small sample size, it is not advisable to draw any conclusions at this stage. As such, the more important story on the earnings front pertains to expectations form the coming reports.
About the Zacks Rank
Since 1988, the Zacks Rank has proven that "Earnings estimate revisions are the most powerful force impacting stock prices." Since inception in 1988, #1 Rank stocks have generated an average annual return of +28%. During the 2000-2002 bear market, Zacks #1 Rank stocks gained +43.8%, while the S&P 500 tumbled -37.6%. Also note that the Zacks Rank system has just as many Strong Sell recommendations (Rank #5) as Strong Buy recommendations (Rank #1). Since 1988, Zacks Rank #5 stocks have significantly underperformed the S&P 500 (+3% versus +10%). Thus, the Zacks Rank system allows investors to truly manage portfolio trading effectively.
Zacks "Profit from the Pros" e-mail newsletter offers continuous coverage of the industries and the stocks poised to outperform the market. Click to subscribe to this free newsletter today.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
SOURCE Zacks Investment Research, Inc.
More by this Source
The Zacks Analyst Blog Highlights: Celgene, Biogen, Gilead, Orexigen and Cubist
Dec 05, 2013, 09:30 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.